ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1446

The Optimal Joint Set for Ultrasound Assessment of Synovitis in RA: Results from the Rasch Measurement Model

Elizabeth M.A. Hensor1,2, Alan Tennant3, Philip G. Conaghan1,2, Hilde B Hammer4, Richard J. Wakefield1,2 and Maria Antonietta D'Agostino1,5, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2NIHR Leeds Biomedical Research Centre, Chapel Allerton Hospital, Leeds, United Kingdom, 3Swiss Paraplegic Research, Nottwil, Switzerland, 4Rheumatology, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 5Rheumatology, Versailles-Saint Quentin en Yvelines University- APHP, Ambroise-Paré Hospital, Boulogne-Billancourt, France

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Outcome measures, rheumatoid arthritis (RA) and ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

The recently introduced composite OMERACT-EULAR power Doppler (PD)/grey scale (GS) ultrasound (PDUS) scoring system for RA with a proposed 18 joint set was developed without reference to modern psychometric analysis. We aimed to assess the scoring system and joint selection using the Rasch measurement model, which sets out criteria for measurement of an underlying ‘latent’ quantity, and to propose a refined tool.

Methods:

We included biologic-naïve patients with ACR 1987 RA diagnosis, disease duration <6 months who received abatacept and methotrexate for 24 weeks in a clinical trial[1]. US was performed at weeks 0, 1, 2, 4, 6, 8, 12, 16, 20 & 24. Bilateral MCPs 1–5, PIPs 1–5, wrist, elbow, shoulder (glenohumeral), knee, ankle (tibiotalar), hind foot (talonavicular and calcaneocuboidal) and metatarsophalangeal joints (MTPs) 1–5 (44 total) were scored 0-3 for GS, PD & PDUS. The scoring system and joint set were assessed for fit to the Rasch model and acceptable reliability (person separation index (PSI) >=0.7). Standardised response mean at 24 weeks was calculated.

Results:

We included 96 patients (mean age 56.5, disease duration <=2 years 43%, 2-10+ years 57%; 83% female). Analysis of the composite score showed that the probability of a joint being assigned a higher score did not consistently increase with the underlying latent quantity i.e. level of inflammation, indicating that assessors were not completely able to distinguish the categories. Shifting the point of transition between a score of 1 and 2, and reserving 3 for GS=3 PD=3 resulted in ordered thresholds. We also found residual correlation between some joints within the proposed 18 joint set, indicating that their scores were not independent. Joints that were only likely to score >0 at high levels of inflammation, beyond the observed range, were prioritised for exclusion. Using revised scoring in a set of 15 joints (bilateral MCPs 1-5, right side wrist, PIPs 2&5, MTPs 2&5) yielded fit to the Rasch model (item-trait interaction Chi-square p=0.647) and acceptable reliability (PSI=0.77; Cronbach’s alpha=0.81). Using linear-scaled (transformed) estimates from the Rasch model for the revised scoring in the 15 joint set showed significantly greater sensitivity to change than using original scoring in either the 44 joint set (mean difference (bootstrapped 95% CI)= -0.33 (-0.59, -0.06), p=0.016) or 18 joint set (-0.42 (-0.71, -0.13), p=0.004) in 74 patients with 24 week data available (Table 1).

Conclusion:

Refining both the scoring system and the joint set using the Rasch model resulted in enhanced sensitivity to change. Future work will validate these findings in external data in order to confirm that the proposed changes further improve the sensitivity and reliability of US in clinical trials.

1. D’Agostino et al. Ann Rheum Dis 75:1763-9

Table 1: Standardised response means calculated using original or revised PDUS scoring

Standardised response mean at 26 weeks (n=74)

Joints included

Original PDUS scoring

Revised PDUS scoring

44 (22 paired)

-1.05

-1.11

18 (9 paired)

-0.96

-0.98

15 (5 paired, 5 single) – raw score

-1.20

-1.40

15 (5 paired, 5 single) – Rasch-transformed

N/A

-1.38


Disclosure: E. M. A. Hensor, None; A. Tennant, None; P. G. Conaghan, None; H. B. Hammer, None; R. J. Wakefield, None; M. A. D'Agostino, None.

To cite this abstract in AMA style:

Hensor EMA, Tennant A, Conaghan PG, Hammer HB, Wakefield RJ, D'Agostino MA. The Optimal Joint Set for Ultrasound Assessment of Synovitis in RA: Results from the Rasch Measurement Model [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/the-optimal-joint-set-for-ultrasound-assessment-of-synovitis-in-ra-results-from-the-rasch-measurement-model/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-optimal-joint-set-for-ultrasound-assessment-of-synovitis-in-ra-results-from-the-rasch-measurement-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology